Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hydrocodone Bitartrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2012
Lead Product(s) : Hydrocodone Bitartrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2012
Lead Product(s) : Armodafinil
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Moffitt Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2011
Lead Product(s) : Armodafinil
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Moffitt Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2011
Lead Product(s) : Hydrocodone Bitartrate
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2011
Lead Product(s) : Hydrocodone Bitartrate
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocodone Bitartrate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2011
Lead Product(s) : Hydrocodone Bitartrate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : NYU Langone Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2011
Lead Product(s) : Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : NYU Langone Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Armodafinil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2011
Lead Product(s) : Armodafinil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAS 26833-87-4
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 07, 2011
Lead Product(s) : CAS 26833-87-4
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Armodafinil
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : NYU Langone Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2010
Lead Product(s) : Armodafinil
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : NYU Langone Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
